Immune cells overexpressing LHX2 and their applications

By overexpressing LHX2 in immune cells, engineered immune cells were constructed, which solved the problem of immune cell depletion under antigen stimulation in vivo, enhanced the function of NK cells and iPSC-derived NK cells, prolonged their survival in vivo, reduced the risk of CRS, and expanded their application to the treatment of chronic viral infections.

CN123107934APending Publication Date: 2026-11-17SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611346930.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-01
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing immunotherapy products are easily depleted under continuous antigen stimulation in vivo, exhibiting decreased proliferative capacity, weakened killing effect, and increased apoptosis levels. In particular, the survival capacity of NK cells and iPSC-derived immune cells is insufficient, limiting their application in solid tumors and chronic infectious diseases.

Method used

Engineered immune cells were constructed by overexpressing LHX2 or its functional variants in immune cells, retaining the two N-terminal LIM zinc finger domains and the C-terminal homeobox DNA-binding domain. These cells were then used to bind chimeric antigen receptors or exogenous T-cell receptors, and the LHX2 gene was introduced into the cells via a viral vector and overexpressed.

Benefits of technology

It significantly enhances the long-term killing ability of T-cell products, strengthens the combined function of NK cells and iPSC-derived NK cells, prolongs in vivo survival, reduces the risk of cytokine release syndrome, and expands its application to the long-term control of chronic persistent viral infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107934A_ABST
    Figure CN123107934A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedicine and immunotherapy technology, and discloses engineered immune cells that enhance the stemness and long-term survival ability of immune cells through LHX2 gene overexpression, as well as their applications. The engineered immune cells of this invention are T cells, NK cells, or iPSC-induced differentiation-derived immune cells that overexpress LHX2 or its functionally active variants. This invention demonstrates that LHX2 overexpression significantly enhances the expansion capacity of T cells, NK cells, CAR-T, TCR-T, TIL, CAR-NK, and iPSC-NK cells; LHX2-overexpressing cells exhibit low exhaustion during multiple rounds of antigen stimulation, low PD-1 / Tim-3 / LAG-3 expression levels, and increased TCF1 expression; LHX2-overexpressing cells exhibit good long-term killing function while continuously expanding. The products of this invention can be used for the treatment of tumors, autoimmune diseases, inflammatory diseases, and viral infections.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedicine and immunotherapy technology, specifically relating to immune cells that overexpress LHX2 and their applications. Background Technology

[0002] Immunotherapy has demonstrated significant efficacy in treating various diseases, such as hematological malignancies and some solid tumors. Representative products include chimeric antigen receptor T cells (CAR-T), T cell receptor-engineered T cells (TCR-T), tumor-infiltrating lymphocytes (TIL), and CAR-NK. However, in the tumor or infection microenvironment continuously stimulated by antigens in vivo, these therapies are prone to cell exhaustion, manifested as decreased proliferative capacity, weakened killing effect, and increased apoptosis levels. This is a key bottleneck limiting their long-term efficacy.

[0003] In particular, NK cell therapy products face significant technical limitations: in vitro expansion is difficult and has limited expansion fold, and the survival time after reinfusion is short and the in vivo retention capacity is severely insufficient. This greatly restricts the application of NK and CAR-NK products in solid tumors and chronic persistent infectious diseases. Furthermore, while the directed differentiation of induced pluripotent stem cells (iPSCs) to obtain NK or T cells is an important development direction for universal off-the-shelf cell products, iPSC-derived immune cells generally suffer from insufficient stemness and are also prone to exhaustion and apoptosis after continuous antigen stimulation, limiting their actual therapeutic efficacy.

[0004] Currently, some studies have attempted to overcome the exhaustion problem of immune cells through genetic modification, such as knocking out negative regulatory genes like SHP-1 / 2 and PTPN2, or overexpressing transcription factors like c-Jun. However, most of these existing modification strategies primarily target T cells and lack universal strategies adapted to NK cells or iPSC-derived immune cells, resulting in extremely limited functional enhancement for the latter. Furthermore, some anti-exhaustion strategies significantly amplify initial activation signals in cells, posing a potential risk of inducing severe cytokine release syndrome (CRS).

[0005] LHX2 (LIM homeobox 2) belongs to the LIM homeobox transcription factor family. Its N-terminus contains two LIM zinc finger domains (mediating interactions with intracellular molecules), and its C-terminus contains a homeobox DNA-binding domain. LHX2 is known to participate in the regulation of physiological processes such as central nervous system development, hair follicle stem cell homeostasis, and hematopoietic stem cell self-renewal. However, to date, there have been no reports on introducing LHX2 into effector T cells, NK cells, or iPSC-derived immune cells to improve their resistance to exhaustion, enhance their long-term survival in vivo, and resist apoptosis. Therefore, developing novel strategies for LHX2-based immune cell modification to address the limitations in T cell and NK cell expansion and short lifespan, improve the functional defects of iPSC-derived cells, and expand cell therapy options for diseases such as chronic viral infections has extremely important clinical translational value. Summary of the Invention

[0006] The purpose of this invention is to overcome at least one deficiency of the prior art and to provide immune cells that overexpress LHX2 and their applications.

[0007] The technical solution adopted in this invention is: In a first aspect, the present invention provides an engineered immune cell that overexpresses LHX2 or a functionally active variant thereof, wherein the LHX2 or the functionally active variant thereof retains two N-terminal LIM zinc finger domains and a C-terminal homology box DNA-binding domain.

[0008] In some embodiments, the engineered immune cells further comprise a chimeric antigen receptor or an exogenous T cell receptor capable of recognizing a target antigen; and / or the nucleotide sequence of the LHX2 gene is selected from the nucleotide sequence shown in SEQ ID NO:1 or its conserved alternative sequence; and / or the engineered immune cells are selected from T cells, NK cells, or immune cells derived from iPSC-induced differentiation.

[0009] In some embodiments, the chimeric antigen receptor comprises: an antigen-binding domain, a hinge region, a transmembrane domain, at least one co-stimulatory signaling domain, and a CD3ζ signaling domain; the co-stimulatory signaling domain is selected from CD28, 4-1BB, ICOS, OX40, CD27, or a combination thereof.

[0010] In some embodiments, the nucleotide sequence of the chimeric antigen receptor comprises the sequence shown in SEQ ID NO:2 or SEQ ID NO:5; or the nucleotide sequence of the exogenous T cell receptor comprises the sequence shown in SEQ ID NO:4.

[0011] In some embodiments, the engineered immune cells are selected from CAR-NK cells, iPSC-NK cells, iPSC-T cells, CAR-T cells, TCR-T cells, tumor-infiltrating lymphocytes (TILs), or γδ-T cells.

[0012] In a second aspect, the present invention provides a method for constructing engineered immune cells as described in the first aspect, characterized in that it includes the step of introducing the LHX2 gene into immune cells in vitro or in vivo and causing it to be overexpressed.

[0013] In some embodiments, the LHX2 gene is introduced into immune cells via a viral vector or a non-viral vector; the viral vector is a lentiviral vector or a retroviral vector; the non-viral vector is a transposon system or mRNA.

[0014] Thirdly, the present invention provides a pharmaceutical composition comprising the engineered immune cells described in the first aspect and a pharmaceutically acceptable carrier or excipient.

[0015] Fourthly, the present invention provides the use of the engineered immune cells described in the first aspect or the pharmaceutical composition described in the third aspect in the preparation of immunotherapeutic drugs.

[0016] In some embodiments, the disease treated by the drug is selected from tumors, autoimmune diseases, or inflammatory diseases.

[0017] The beneficial effects of this invention are: This invention is the first to demonstrate that overexpression of LHX2 not only significantly enhances the long-term killing ability of T-cell products (CAR-T, TCR-T, TIL), but also greatly improves the comprehensive function of primary NK cells, CAR-NK, and iPSC-derived NK cells. This strategy effectively solves the key technical pain points of existing NK cell therapy products, such as the difficulty of in vitro expansion and the extremely short survival time after reinfusion, thus endowing engineered immune cells with extremely strong long-term in vivo survival capabilities.

[0018] The modified immune cells of this invention exhibit "restrained" initial activation characteristics, with no significant difference in effector cytokine secretion compared to the control group under the first round (short-term) antigen stimulation. However, after multiple rounds and repeated antigen stimulation, LHX2-overexpressing cells show extremely low exhaustion (significantly downregulated PD-1, Tim-3, and LAG-3 expression levels) and maintain robust proliferation and long-term killing function. This phenotype, which does not blindly amplify initial effector signals, greatly reduces the potential risk of inducing cytokine release syndrome (CRS) in clinical applications.

[0019] Mechanistic studies have shown that LHX2 overexpression can significantly upregulate the expression of the stemness-associated transcription factor TCF1. TCF1 is a core transcription factor that maintains the stemness-like exhaustion state of immune cells. By activating this pathway, LHX2 endows immune cells with self-renewal ability and long-term functional persistence in a continuous high-pressure antigen microenvironment.

[0020] Leveraging the robust long-term in vivo survival capabilities of the modified cells, this invention is not only applicable to the treatment of tumors and autoimmune / inflammatory diseases, but also, more significantly, expands its application to the long-term control of chronic persistent viral infections (such as CMV infection). Furthermore, the LHX2 modification technology of this invention is perfectly compatible with the preparation of engineered immune cells derived from iPSC stem cells, providing solid technical support for the future industrial-scale production of universal off-the-shelf cell therapy products. Attached Figure Description

[0021] Figure 1 Figure 1 shows the construction and in vitro functional testing of LHX2-overexpressing NK / CAR-NK cells. Figure A shows the comparison of LHX2 expression levels, Figure B shows the in vitro expansion curve of LHX2-overexpressing NK cells, Figure C shows the results of multiple rounds of killing experiments, Figure D shows the amount of IFN-γ secreted in the supernatant of multiple rounds of killing experiments, and Figure E shows the expression detection of exhaustion markers (PD-1, Tim-3, LAG3) after the fourth round of killing.

[0022] Figure 2 The figures show the antiviral effect of LHX2 overexpressing NK cells in a humanized mouse model of chronic CMV infection. Figure A compares the CMV viral load in peripheral blood of mice, Figure B compares the CMV viral load in the lungs and spleen of mice, Figure C shows the number of human NK cells in the spleen of mice, and Figure D shows the expression of exhaustion markers (PD-1, Tim-3) in NK cells of the spleen of mice.

[0023] Figure 3 Figure 1 shows the construction and functional validation of LHX2-overexpressing NK cells derived from iPSCs. Figure A compares the LHX2 expression levels in iPSCs, and Figure B shows the CD34 expression during directed differentiation of iPSCs. + Cell proportion statistics: Figure C shows the in vitro expansion curve of LHX2-overexpressing iPSC-NK cells, and Figure D shows the comparison of the in vitro killing efficiency of iPSC-NK cells against tumor organoids.

[0024] Figure 4Figure 1 shows the construction and testing of LHX2 gene-overexpressing CAR-T cells. Figure 2 shows the comparison of LHX2 expression levels, Figure 3 shows the in vitro expansion curve of LHX2-overexpressing CAR-T cells, Figure 4 shows the results of multiple rounds of killing experiments, Figure 5 shows the amount of IFN-γ secreted in the supernatant of multiple rounds of killing experiments, Figure 6 shows the expression detection of exhaustion markers (PD-1, Tim-3, LAG3) after the fourth round of killing, and Figure 7 shows the TCF-1 expression level of LHX2-overexpressing CAR-T cells after the fourth round of killing.

[0025] Figure 5 The graphs show the anti-tumor effects of LHX2-overexpressing CAR-T cells in an in vivo tumor model. Figure A shows the tumor growth curve and mouse survival curve in the in vivo xenograft tumor model. Figure B shows the comparison of the number of CAR-T cells in peripheral blood. Figure C shows the positive proportion of exhaustion markers (PD-1, LAG3, and TIM-3) in tumor-infiltrating T cells.

[0026] Figure 6 The graphs show the anti-tumor effects of LHX2-overexpressing TCR-T cells in an in vivo tumor model. Figure A shows the tumor growth curve and mouse survival curve in the in vivo xenograft tumor model. Figure B shows the comparison of the number of TCR-T cells in peripheral blood. Figure C shows the positive proportion of exhaustion markers (PD-1 and TIM-3) in tumor-infiltrating T cells.

[0027] Figure 7 Figure 1 shows the construction and in vitro testing of TIL cells overexpressing LHX2. Figure A shows the comparison of LHX2 expression levels, and Figure B shows the results of the in vitro killing experiment of TILs. Detailed Implementation

[0028] The following disclosure provides many different implementations or examples for different ways of implementing the present invention. Example 1: Construction and in vitro functional verification of LHX2-overexpressing CAR-NK cells

[0029] 1.1 Vector Construction and Virus Packaging Vector construction: Obtain the codon-optimized human LHX2 CDS sequence (SEQ ID NO:1); construct a CAR expression cassette targeting the CD19 antigen (SEQ ID NO:5); in this embodiment, a dual independent promoter lentiviral vector pLV-EF1α-LHX2-PGK-CAR is used, with the EF1α promoter driving LHX2 gene expression and the PGK promoter driving CD19-CAR expression; at the same time, a control vector pLV-EF1α-empty-PGK-CAR is constructed.

[0030] Lentiviral packaging: S1) The recombinant vector and packaging plasmids psPAX2 and pMD2.G were co-transfected into HEK-293T cells. Transfection system preparation: Centrifuge tube A: Opti-MEM 500 μL + main plasmid 10 μg + pMD2.G 5 μg + psPAX 25 μg + P3000 40 μL; Centrifuge tube B: Opti-MEM 500 μL + Lipo3000 40 μL; Slowly add the mixture from tube B to tube A, mix gently, and incubate at room temperature for 18 min. S2) Add the mixed transfection system to a HEK-293T culture dish; replace with complete DMEM medium 5 h after transfection; collect cell culture supernatant 48 h; centrifuge at 400g for 5 min and filter through a 0.45μm filter; S3) Use an Ultra-15 centrifuge filter to centrifuge at 5000 rpm for 50 min to complete virus concentration; after concentration, aliquot the virus and store at -80℃ for later use.

[0031] Lentiviral titer assay: S1) Dilute the concentrated lentivirus stock solution 10-fold serially; S2) Take 2.5 × 10 5 The HEK-293T cells and serially diluted virus were thoroughly mixed and seeded into 24-well plates. S3) Cultured at 37℃ and 5% CO2; the culture medium was changed after 24 hours; cells were collected after 48 hours and the percentage of transgenic positive cells was detected by flow cytometry.

[0032] Virus titer calculation formula: , where m represents the proportion of transgenic positive cells.

[0033] 1.2 Cell transduction and overexpression detection NK cell isolation, activation, and lentiviral transduction: CD56 was isolated from peripheral blood PBMCs of healthy donors. + NK cells were cultured in X-VIVO-15 medium supplemented with 5% human AB serum, IL-2 100 IU / mL, and IL-15 20 ng / mL. Cells were activated for 24-48 hours. Concentrated lentivirus was added at an MOI of 10-30 for transduction. Cells were cultured for another 7-10 days to obtain LHX2-CAR-NK cells. The control group consisted of CAR-NK cells expressing only CAR. qRT-PCR was used to verify LHX2 overexpression. Total RNA was extracted from both LHX2-CAR-NK and control CAR-NK cells and reverse transcribed to synthesize cDNA. qRT-PCR was performed using LHX2-specific primers, with GAPDH as an internal reference gene.

[0034] Test results as follows Figure 1In LHX2-CAR-NK cells, the expression level of LHX2 mRNA was 5-7 times that of the control group.

[0035] In vitro amplification capacity assay: Both groups of cells were cultured in NK complete medium for 21 days, and cell counting and passage were performed every 2-3 days.

[0036] The results are as follows Figure 1 B: The amplification fold of LHX2-CAR-NK reached 3.2 times that of the control group on day 14; the amplification fold reached 3.0 times that of the control group on day 21, P < 0.001.

[0037] 1.3 In vitro expansion and multi-round killing function assessment Multi-round target cell killing and cytokine detection: CD19-positive Raji cells were selected as target cells; the effector-to-target ratio was set at 1:1; fresh target cells were replaced every 72 hours, and four rounds of killing experiments were conducted continuously; cell killing efficiency was determined by the LDH release method; the co-culture supernatant was collected, and the IFN-γ secretion level was detected by an ELISA kit.

[0038] The results are as follows Figure 1 In the first round of killing (C / 1D), there were no statistically significant differences in cell killing efficiency and IFN-γ secretion levels between the two groups. As the number of killing rounds increased, the CAR-NK killing ability of the control group rapidly declined. In the fourth round of killing, the CAR-NK killing rate of the control group was only 23.1%, while LHX2-CAR-NK still maintained a killing efficiency of 61.3%.

[0039] Flow cytometry results as follows Figure 1 E: The expression levels of PD-1, Tim-3, and LAG-3 in the LHX2-CAR-NK group were downregulated by 51%, 48%, and 43%, respectively, compared with the control group.

[0040] The above results indicate that LHX2 overexpression not only enhances the anti-exhaustion ability of T cell products, but is also applicable to NK cells and CAR-NK cells, significantly improving the durable killing function of NK cells after repeated antigen exposure. Example 2: Antiviral effect of LHX2-NK in a humanized mouse model of chronic CMV infection

[0041] 2.1 Animal Model Construction and Cell Reinfusion S1) Construction of a humanized NSG-CMV persistent infection mouse model: S2) Six- to eight-week-old female NSG-immunodeficient mice were selected; S3) Mice were irradiated with a sublethal dose of radiation (200 cGy); S4) Human CD34 infused via tail vein 24 hours after irradiation+ Hematopoietic stem cells were used to reconstruct the human immune system; the reconstruction period was 12 weeks; the proportion of human CD45+ cells in peripheral blood of mice was detected by flow cytometry, and mice with a humanization rate greater than 60% were included in subsequent experiments. A persistent chronic human cytomegalovirus infection model was established by intraperitoneal injection of human CMV virus solution into qualified humanized mice; tail vein blood was collected every 7 days, and peripheral blood CMV virus copy number was detected by qPCR; persistent infection was confirmed (virus copy number remained stable at 10). 4 -10 5 Cell reinfusion therapy experiments were conducted after (copies / mL).

[0042] Grouping of experimental animals and cell reinfusion: S1) Successfully modeled humanized CMV chronically infected mice were randomly divided into 3 groups, n=8 mice in each group: Group 1: PBS control group: 200 μL sterile PBS was injected via tail vein; Group 2: Unmodified NK control group (NK-Control): 5 × 10⁻⁶ μL of sterile PBS was reinfused via tail vein. 8 Human NK-Control cells transduced with empty vector were resuspended in 200 μL PBS; Group 3: LHX2-NK experimental group: 5 × 10⁶ cells were infused via tail vein. 8 LHX2-NK cells were resuspended in 200 μL PBS; S2) All mice were housed in an SPF-grade animal facility; their general condition and weight changes were observed. S3) Peripheral blood samples were collected from the tail vein of mice on days 7, 14, 21, and 28 after reinfusion. S4) All mice were euthanized 28 days after reinfusion, and spleen and lung tissue samples were collected.

[0043] 2.2 In vivo antiviral and survival capacity detection Sample processing and CMV viral load: S1) qPCR detection of peripheral blood samples: extraction of whole blood genomic DNA; S2) Tissue samples: Spleen and lung tissues were ground and lysed to extract genomic DNA; S3) Using human CMV-specific primers and probes, the CMV viral DNA copy number in the samples was detected by real-time quantitative qPCR; viral load units: copies / mL (blood), copies / mg tissue. Simultaneously, flow cytometry was used to detect human CD45 in peripheral blood and spleen. + CD56 + The proportion and absolute number of NK cells; detection of the expression levels of NK cell depletion markers PD-1 and Tim-3.

[0044] Experimental results: Peripheral blood CMV viral load such as Figure 2 A: On day 7 after reinfusion, there was no statistically significant difference in the viral load in the peripheral blood of the three groups of mice, all of which were within 10. 4 ~10 5 On day 14 after reinfusion: the viral load in the PBS group continued to increase, reaching (1.12±0.21)×10⁻⁶. 5 copies / mL; the viral load in the NK-Control group decreased slightly to (7.43±1.35)×10. 4 copies / mL; viral load in the LHX2-NK experimental group decreased significantly to (2.26±0.58)×10 4 copies / mL (P < 0.01). Endpoint on day 28 after reinfusion: Peripheral blood viral load in the PBS control group was (1.47 ± 0.33) × 10⁻⁶ copies / mL (P < 0.01). 5 The viral load in the NK-Control group was (6.15±1.08)×10⁻⁶ copies / mL; 4 copies / mL; the peripheral blood CMV viral load in the LHX2-NK experimental group decreased to (8.32±2.14)×10 2 The number of copies / mL decreased by approximately 74-fold compared to the unmodified NK control group (P < 0.001).

[0045] Viral load in organs and tissues (day 28) Figure 2 B: Lung tissue (major target organ for CMV): PBS group (2.35±0.41)×10 4 copies / mg; NK-Control group (1.06±0.24)×10 4 copies / mg; LHX2-NK experimental group (4.21±1.13)×10 2 copies / mg, significantly reduced viral load.

[0046] Detection of in vivo survival and depletion of human NK cells: like Figure 2 C / 2D: Flow cytometry results of mouse spleen on day 28: LHX2-NK group human CD45 + CD56 + The absolute number of NK cells was 3.8 times that of the NK-Control control group; the proportion of PD-1 and Tim-3 positive exhausted cells in the LHX2-NK group was reduced by 46% and 42% respectively compared with the control group, indicating that LHX2-NK can better maintain cell survival and resist exhaustion under the continuous stimulation of chronic viral antigens in vivo.

[0047] The above results indicate that in a humanized mouse model of chronic persistent CMV infection, LHX2-overexpressing NK cells significantly enhance their in vivo survival capacity, resist viral antigen-induced cell exhaustion, and effectively reduce CMV viral load in vivo, demonstrating that LHX2-modified NK cells have clear therapeutic potential in chronic persistent viral infections. Example 3: Construction and functional verification of iPSC-derived LHX2-NK cells

[0048] Carrier construction: Obtain the CDS sequence (SEQ ID NO:1) of human LHX2 after codon optimization; in this embodiment, a single-expression lentiviral vector pLV-EF1α-LHX2 for iPSC cell infection was constructed, with LHX2 gene expression driven only by the EF1α promoter; at the same time, an empty vector control group pLV-EF1α-empty was constructed, which has no LHX2 target gene inserted.

[0049] Lentiviral packaging: S1) Recombinant vector pLV-EF1α-LHX2 or control empty vector was co-transfected with packaging plasmids psPAX2 and pMD2.G into HEK-293T cells. Transfection system preparation: Centrifuge tube A: Opti-MEM 500 μL + main plasmid 10 μg + pMD2.G 5 μg + psPAX2 5 μg + P3000 40 μL; Centrifuge tube B: Opti-MEM 500 μL + Lipo3000 40 μL; S2) Slowly drop the mixture from tube B into tube A, mix gently, and let stand at room temperature for 18 minutes; add the mixed transfection system to a HEK-293T culture dish; S3) Replace with complete DMEM medium 5 h after transfection; collect cell culture supernatant 48 h later; S4) Centrifuge at 400g for 5 min, then filter through a 0.45μm filter; S5) Use an Ultra-15 centrifugal filter to centrifuge at 5000 rpm for 50 min to complete virus concentration; S6) Concentrated virus aliquots are stored at -80℃ for later use.

[0050] Lentiviral titer assay: S1) Dilute the concentrated lentivirus stock solution 10-fold serially; S2) Take 2.5 × 10 5 The HEK-293T cells and serially diluted virus were thoroughly mixed and seeded into 24-well plates; cultured at 37°C and 5% CO2. S3) Change the culture medium after 24 hours; collect cells after 48 hours and detect the percentage of transgenic positive cells by flow cytometry.

[0051] Virus titer calculation formula: , where m represents the proportion of transgenic positive cells. Viral titers were calculated as shown in Table 1 below: Table 1 Virus <![CDATA[Positive rate (10 -2 dilution)]]> Titration (TU / mL) pLV-EF1α-LHX2 3.86% <![CDATA[9.66×10 6 ]]> pLV-EF1α-empty 4.13% <![CDATA[1.03×10 7 ]]> iPSC cell lentiviral infection and stable strain screening: S1) Resuscitate human induced pluripotent stem cells (iPSCs), seed them in Matrigel-coated culture plates, and culture them in mTeSR-1 complete medium; S2) When the cell confluence reaches 40%-50%, add concentrated lentivirus at MOI=15-40; infect experimental group iPSCs with pLV-EF1α-LHX2 virus, and infect control group iPSCs with pLV-EF1α-empty empty vector virus. S3) Replace with fresh mTeSR-1 medium 24 hours after infection; pass through 2-3 generations, screen for LHX2 high expression clones by qPCR, select single clones, amplify and culture to obtain stable iPSC strains that stably overexpress LHX2 and control iPSC empty vector strains.

[0052] qRT-PCR validation of LHX2 overexpression in iPSC cells: S1) Take iPSC-LHX2 cells from the experimental group and iPSC-empty cells from the control group respectively, extract total RNA from the cells, and reverse transcribe it to synthesize cDNA; S2) qRT-PCR detection was performed using LHX2-specific primers, with GAPDH as an internal reference gene.

[0053] The results showed that the expression level of LHX2 mRNA in iPSC-LHX2 cells was 6-8 times that in the control group iPSCs. Figure 3 A).

[0054] iPSCs differentiate into CD34. + Hematopoietic progenitor cells: S1) The selected stable iPSC cells and control group iPSC cells were digested, seeded according to the hematopoietic differentiation protocol, and used hematopoietic induction differentiation medium. S2) Add BMP4, VEGF, and SCF cytokines sequentially, and culture at 37℃ and 5% CO2 for 12-14 days; collect suspension cells and enrich CD34 using a CD34 magnetic bead sorting kit. + Hematopoietic progenitor cells.

[0055] S3) Flow cytometry detection of CD34-positive cell purity, CD34 + Cells with a purity greater than 85% were used for subsequent NK-induced differentiation.

[0056] CD34 + Induction of hematopoietic progenitor cells into NK cells: S1) The sorted CD34 + Hematopoietic progenitor cells were seeded into NK induction medium, which was based on X-VIVO-15 and supplemented with 5% human AB serum, along with cytokines SCF 30 ng / mL, IL-7 20 ng / mL, and IL-15 20 ng / mL. S2) Cultured at 37℃ and 5% CO2 for 28 days; replace half of the NK induction medium with fresh NK induction medium and add the corresponding cytokines every 3-4 days. S3) After the culture was completed, the cells were harvested to obtain iPSC-LHX2-NK cells and control group iPSC-NK cells.

[0057] Flow cytometry identification of CD45, a marker on the surface of NK cells + CD56 + CD3 - NK cell purity > 80% Figure 3 B).

[0058] Detection of in vitro expansion capacity of iPSC-NK cells: iPSC-LHX2-NK cells and control iPSC-NK cells were cultured in complete NK medium for 21 days, with IL-2 100 IU / mL and IL-15 20 ng / mL added to the medium; cell counting and passage were performed every 2-3 days.

[0059] The results showed that the amplification fold of iPSC-LHX2-NK reached 2.9 times that of the control group on day 14; and 2.6 times that of the control group on day 21 (P < 0.001). Figure 3 C).

[0060] In vitro killing ability of tumor organoids: S1) Select tumor organoids derived from hematologic malignancies and place them in a 48-well plate matrix gel; S2) iPSC-LHX2-NK cells and control group iPSC-NK cells were added at an effector-to-target ratio of 2:1; co-cultured at 37℃ and 5% CO2 for 24 h. S3) The cell killing efficiency was detected by the LDH release method: the absorbance was read at 490 nm using an ELISA reader according to the kit instructions, and the killing rate was calculated.

[0061] The results showed that the 24-hour killing efficiency of iPSC-NK cells against organoids of hematological malignancies in the control group was 36.2%; while the 24-hour killing efficiency of iPSC-LHX2-NK cells reached 72.7%. Figure 3 C).

[0062] The above results indicate that LHX2 overexpression can significantly enhance the in vitro expansion capacity and tumor-killing function of iPSC-derived NK cells, and also has a functional enhancement effect on iPSC-derived immune cell products. Example 4: In vitro functional validation of LHX2-overexpressing CAR-T cells

[0063] 4.1 Construction of CAR and LHX2 expression vectors: 1) Download the CDS sequence of the LHX2 gene from NCBI, and then perform codon optimization on a portion of the gene sequence to enhance its expression. These optimization methods include, but are not limited to: human codon usage preference, appropriate GC content, stable mRNA secondary structure, elimination of repetitive sequences and hidden splice sites and unnecessary restriction enzyme sites, while preventing the depletion of the tRNA library in the cell, to obtain the coding sequence (CDS) of the human LHX2 gene, whose nucleic acid sequence is shown in SEQ ID NO:1.

[0064] 2) Construct a CAR sequence targeting MSLN, wherein the CAR comprises, from N-terminus to C-terminus, a signal peptide, a single-chain antibody against tumor-associated antigen (scFv), a hinge region, a transmembrane region, a co-stimulatory signaling domain, and a CD3ζ signaling domain, and its nucleic acid sequence is shown in SEQ ID NO:2.

[0065] 3) The CAR expression cassette and LHX2 expression cassette were cloned into a lentiviral expression vector (pCDH vector). The CAR and LHX2 were linked by a P2A self-cleaving peptide (SEQ ID NO:3). The constructed vector was named pLV-CAR-P2A-LHX2.

[0066] 4.2 Lentiviral preparation: S1) HEK-293T cells were transfected with pLV-CAR-P2A-LHX2, psPAX2, and pMD2.G vectors containing the LHX2 gene obtained in step 1. The transfection system was prepared as follows: (1) Centrifuge tube A: Opti-MEM 500 μL + main plasmid 10 μg + pMD2.G 5 μg + psPAX 25 μg + p3000 40 μL; (2) Centrifuge tube B: Opti-MEM 500 μL + Lipo3000 40 μL. The mixture in centrifuge tube B was slowly dripped into centrifuge tube A, and after being gently mixed with a pipette, it was allowed to stand at room temperature for 15-20 min. S2) Add the transfection system to HEK-293T cells. After 5 hours of transfection, discard the supernatant and add 10 ml of DMEM complete medium to each dish. S3) Place in a 37℃, 5% CO2 incubator for further incubation; S4) After 48 hours, the culture supernatant of the transfected 293T cells was collected; centrifuged at 400g for 5 min; filtered through a 0.45μm filter, and the filtrate obtained was the original solution of the recombinant lentivirus. S5) Concentrate lentivirus using an Ultra-15 centrifugal filter device, centrifuge at 5000 rpm for 50 min; S6) The concentrated lentivirus is aliquoted and stored in a -80℃ freezer for later use; S7) Cell counting was performed on the cleaned and digested HEK-293T cells; S8) Dilute the lentivirus concentrate stock solution with 10-fold serial dilutions (50×, 500×, 5000×, 50000×). Take 2.5×10 5 Each HEK-293T cell was added to its corresponding centrifuge tube, with each centrifuge tube containing 500 μL of culture medium, virus, and cell mixture. After mixing, the mixture was transferred to a 24-well plate. S9) After culturing in a 37℃, 5% CO2 incubator for 24 hours, the culture medium was replaced; after 48 hours, infected HEK-293T cells were collected, and the proportion of transgene-positive cells was detected by flow cytometry to calculate the viral titer.

[0067] Lentiviral titer calculation method: , where m is the proportion of cells that are positive for transgene expression.

[0068] 4.3 Isolation, activation, and transduction of T cells: (1) Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood of healthy donors or autologous blood of patients and CD3+ T cells were sorted using CD3 microbeads.

[0069] (2) The sorted T cells were activated with DynabeadsCD3 / CD28 and cultured in T cell culture medium (X-VIVO15 with 5% human AB serum) containing IL-2 (50 IU / mL).

[0070] (3) After activation for 24-48 hours, concentrated recombinant lentivirus was added at an MOI of 5-50 for transduction. After transduction, the cells were cultured for 6-8 days to obtain CAR-T cells overexpressing LHX2, which were named CAR-TLHX2 cells. At the same time, CAR-T cells transduced only with CAR and not with LHX2 were prepared as a control (named CAR-T Control cells).

[0071] 4.4 Detection of LHX2 overexpression: Total RNA was extracted from CAR-TLHX2 cells and CAR-T Control cells, reverse transcribed into cDNA, and then detected by qRT-PCR using LHX2-specific primers, with GAPDH or β-actin as internal controls.

[0072] The results showed that the expression level of LHX2 mRNA in CAR-TLHX2 cells was significantly upregulated compared with that in CAR-T Control cells. Figure 4 A).

[0073] The constructed LHX2-overexpressing CAR-T cells (LHX2-CAR-T) and control CAR-T cells (Ctrl-CAR-T) were expanded and cultured in vitro in complete medium containing IL-2 (100 IU / mL). The cell count was counted and passaged every 2-3 days, and the cells were observed continuously for 21 days.

[0074] Results: Compared with control CAR-T cells, LHX2-overexpressing CAR-T cells exhibited significantly enhanced expansion capacity throughout the culture period. Specifically, the total cell expansion of LHX2-CAR-T cells reached 2.7 times that of the control group on day 14 of culture (P<0.01); and the terminal expansion fold at day 21 reached 3.4 times that of the control group (P<0.001). Figure 4 B).

[0075] 4.5 Detection of IFN-γ effector cytokine secretion levels LHX2-CAR-T cells and control CAR-T cells were co-cultured with target antigen-positive tumor cells at an effector cell:target cell ratio of 1:1. Fresh target cells were replaced every 72 hours, and the number of effector cells was counted. Four rounds of killing experiments were performed to assess the cumulative killing capacity and effector cell survival rate after multiple rounds of repeated antigen stimulation. The supernatant was collected to detect the secretion level of IFN-γ effector cytokines.

[0076] Results: Under short-term co-culture conditions with a single round of killing, there was no statistically significant difference in the in vitro killing ability between LHX2-overexpressing CAR-T cells and control CAR-T cells (P>0.05). After multiple rounds of killing, the CAR-TLHX2-overexpressing group showed an overwhelming advantage in killing target cells compared to the CAR-T control group (P<0.05). Figure 4 C).

[0077] Under short-term co-culture conditions following a single round of cell death, there was no statistically significant difference in IFN-γ cytokine secretion levels between LHX2-overexpressing CAR-T cells and control CAR-T cells (P>0.05). However, after multiple rounds of cell death, the IFN-γ cytokine secretion level in the CAR-TLHX2-overexpressing group showed an overwhelming advantage compared to the CAR-T control group (P<0.05). Figure 4 D).

[0078] 4.6 Detection of expression of exhaustion-related biomarkers and stemness-related molecules After four rounds of killing experiments, T cells were collected from the LHX2-CAR-T group and the control group, and the expression of exhaustion-related markers and stemness-related molecules was detected by flow cytometry and RT-qPCR.

[0079] Results: Exhaustion markers: The positivity rate of PD-1 on the surface of LHX2-overexpressing CAR-T cells was reduced by 55.2% compared with the control group (P<0.01); the positivity rate of Tim-3 was reduced by 49.3% (P<0.01); and the positivity rate of LAG3 was reduced by 47.1% (P<0.01). Under short-term co-culture conditions with a single round of cell death, there was no statistically significant difference in the secretion level of IFN-γ cytokines between LHX2-overexpressing CAR-T cells and control CAR-T cells (P>0.05). After multiple rounds of cell death, the secretion level of IFN-γ cytokines in the CAR-TLHX2-group showed an overwhelming advantage compared with the CAR-T control group (P<0.05). Figure 4 E); TCF1 is a core transcription factor that maintains the stem-like exhaustion state of T cells. Its high expression is a key molecular marker for T cells to maintain self-renewal ability and long-term functional durability

[10] . The mRNA expression level of T cell stemness-related transcription factor TCF1 in LHX2-CAR-T cells was significantly increased, which was 2.8 times that of the control group (P<0.01). Under the short-term co-culture conditions of single-round killing, there was no statistically significant difference in the secretion level of IFN-γ cytokines between LHX2-overexpressing CAR-T cells and control CAR-T cells (P>0.05). After multiple rounds of killing, the secretion level of IFN-γ cytokines in the CAR-TLHX2- group showed an overwhelming advantage compared with the CAR-T control group (P<0.05). Figure 4 F). This invention is the first to demonstrate that LHX2 also activates this pathway in T cells, suggesting that activation of this pathway may be involved in LHX2-mediated maintenance of T cell stemness and anti-exhaustion effects. Example 5: Anti-tumor effect of LHX2 overexpressing CAR-T cells in an in vivo tumor model

[0080] (1) The tumor cell line A549-mesothelin was subcutaneously injected into NSG immunodeficient mice to establish a tumor-bearing model.

[0081] (2) When the tumor volume reaches approximately 50-100 mm 3 At that time, the tumor-bearing mice were randomly divided into the following three groups: Group 1: PBS control group (PBS injected via tail vein) Group 2: Control T cell group (CAR-T control cells injected via tail vein) Group 3: LHX2 overexpressing T cell group (CAR-TLHX2 cells injected via tail vein) (3) Measure tumor volume and mouse weight every 3-4 days and plot tumor growth curve.

[0082] Results: Tumor growth inhibition: Tumors in the PBS group continued to grow rapidly; the control CAR-T group showed some inhibitory effect in the early stage, and the LHX2-CAR-T group maintained a significant tumor inhibition effect on day 28 (P<0.001). Under short-term co-culture conditions with single-round killing, there was no statistically significant difference in IFN-γ cytokine secretion levels between LHX2-overexpressing CAR-T cells and control CAR-T cells (P>0.05). After multiple rounds of killing, the IFN-γ cytokine secretion level in the CAR-TLHX2- group showed an overwhelming advantage compared to the CAR-T control group (P<0.05). Figure 5 A).

[0083] T-cell persistence after infusion: Peripheral blood was collected on day 28 to detect the proportion of CAR-T cells remaining. The proportion of CAR-T cells in the peripheral blood of the LHX2-CAR-T group was approximately 4.5 times that of the control group (P<0.001). Figure 5 B).

[0084] (4) Detection of T cell exhaustion status in tumor tissue Tumor tissue was collected from euthanized mice, and single-cell suspensions were prepared. Flow cytometry staining was performed using anti-human CD45, CD3, CD8, PD-1, and TIM-3 antibodies to detect the exhaustion status of tumor-infiltrating T cells.

[0085] The results showed that the proportion of CD8+ T cells positive for PD-1 and TIM-3 in tumor tissues was significantly reduced in the LHX2-overexpressing T cell group. Figure 5 (C) indicates that LHX2 overexpression promotes the maintenance of T cell function in tumor tissue. Example 6: Antitumor effect of LHX2 overexpressing TCR-T cells

[0086] This embodiment applies the LHX2 overexpression strategy to NY-ESO-1 TCR-T cells. TCR-T cells (TCR-T) targeting the tumor antigen NY-ESO-1 (SEQ ID NO:4) were constructed and overexpressed with the LHX2 gene (LHX2-TCR-T).

[0087] (1) The tumor cell line A375 was subcutaneously injected into NSG immunodeficient mice to establish a tumor-bearing model.

[0088] (2) When the tumor volume reaches approximately 100 mm 3 At that time, the tumor-bearing mice were randomly divided into the following three groups: Group 1: PBS control group (PBS injected via tail vein) Group 2: Control T cell group (tail vein injection of Control TCR-T cells) Group 3: LHX2 overexpressing T cell group (TCR-TLHX2 cells injected via tail vein) (3) Measure tumor volume and mouse weight every 3-4 days and plot tumor growth curve.

[0089] Results: The tumor-suppressing effects of PBS, Control TCR-T, and LHX2-TCR-T were compared by monitoring and comparing tumor volume changes over 35 days. Results showed that the tumors in the PBS group continued to grow rapidly, reaching a volume of 1450–1750 mm² by day 35. 3 The Control TCR-T group showed some inhibitory effect in the early stages, but the tumor relapsed and progressed significantly after day 28, with the terminal volume reaching 885–1130 mm. 3 This suggests that conventional TCR-T has limited long-term tumor control capabilities; the LHX2-TCR-T group showed better tumor suppression throughout the entire treatment process than the control group, with tumor volume maintained at 485–635 mm on day 35. 3 It significantly delayed tumor recurrence. The three groups showed a clear gradient difference: PBS > Control TCR-T > LHX2-TCR-T. Figure 6 A) indicates that LHX2 modification can effectively enhance the in vivo anti-tumor persistence and long-term tumor control ability of TCR-T cells.

[0090] T-cell persistence after infusion: Peripheral blood was collected on day 28 to detect the proportion of CAR-T cells remaining. The proportion of CAR-T cells in the peripheral blood of the LHX2-CAR-T group was approximately 4.3 times that of the control group (P<0.001). Figure 6 B).

[0091] (4) Detection of TCR-T cell exhaustion status in tumor tissue Tumor tissue was collected from euthanized mice, and single-cell suspensions were prepared. Flow cytometry staining was performed using anti-human CD45, CD3, CD8, PD-1, and TIM-3 antibodies to detect the exhaustion status of tumor-infiltrating T cells.

[0092] The results showed that the proportion of CD8+ T cells positive for PD-1 and TIM-3 in tumor tissues was significantly reduced in the LHX2-overexpressing TCR-T cell group. Figure 6 (C) indicates that LHX2 overexpression promotes the functional maintenance of TCR-T cells in tumor tissues. Example 7: Effects of LHX2 overexpression on tumor-infiltrating lymphocyte (TIL) expansion and functional persistence

[0093] (1) Tumor tissue blocks were excised from surgically removed tumor tissue from patients with solid tumors. After being minced, the tumor cells were digested with collagenase / DNase to prepare a single-cell suspension. The tumor cell suspension was inoculated into TIL medium containing a high dose of IL-2 (e.g., 6000 IU / mL) and cultured in a 37°C, 5% CO2 incubator. Half of the medium was replaced and IL-2 was added every 2-3 days. After about 14-28 days of culture, the TIL cells expanded to a sufficient number (e.g., 1×10⁻⁶). 8 (The above) was further amplified using a rapid amplification protocol.

[0094] (2) LHX2 overexpression transduction and functional detection in TIL cells A lentiviral expression vector was constructed to express the LHX2 gene, driven by the EF1α promoter, and named pLV-EF1α-LHX2.

[0095] Packaging lentivirus (method as in Example 4). Amplified TIL cells were activated with anti-CD3 / CD28 antibody. After activation for 24-48 hours, recombinant lentivirus was added at MOI=5 for transduction. After transduction, the cells were cultured for another 7-10 days to obtain LHX2-overexpressing TIL cells, named TIL-LHX2 cells. Simultaneously, TIL cells transduced with the empty vector were prepared as a control (named TIL-Control cells).

[0096] (3) Detection of LHX2 overexpression The expression level of LHX2 in TIL-LHX2 cells was detected by qRT-PCR (method as in Example 1.5). The results showed that the expression level of LHX2 mRNA in TIL-LHX2 cells was significantly higher than that in TIL-Control cells (…). Figure 7 A).

[0097] (4) In vitro killing activity detection Take organoids embedded in Matrigel, add effector cells to each well (cell number calculated according to the preset effector-to-target ratio), and gently mix. Set the following molecular groups: Target organ control group: organoids Effector cell control group: TIL Control group: Organoid + TIL-control group Experimental group: Organoid + TIL-LHX2 group; The co-culture plates were incubated at 37°C in a 5% CO2 incubator. According to the experimental design, the co-culture supernatant was collected after 24 hours. Following the LDH detection kit instructions, the absorbance was read at 490 nm using a microplate reader, and the killing rate was calculated using the following formula:

[0098] The results showed that the TILLHX2 overexpression group cells had significantly higher organoid killing rates than TIL control cells. Figure 7 B). The above results indicate that LHX2 overexpression is also applicable to TIL therapy, which can significantly enhance the anti-tumor function of TIL and provide a new strategy for the treatment of solid tumors with TIL.

[0099] The above is a further detailed description of the present invention and should not be considered as a limitation on the specific implementation of the present invention. For those skilled in the art, simple deductions or substitutions without departing from the concept of the present invention are all within the protection scope of the present invention.

Claims

1. An engineered immune cell, characterized in that, The engineered immune cells overexpress LHX2 or a functionally active variant thereof, wherein the LHX2 or the functionally active variant thereof retains two N-terminal LIM zinc finger domains and a C-terminal homology box DNA-binding domain.

2. The engineered immune cells according to claim 1, characterized in that, The engineered immune cells further comprise a chimeric antigen receptor or exogenous T cell receptor capable of recognizing target antigens; and / or the nucleotide sequence of the LHX2 gene is selected from the nucleotide sequence shown in SEQ ID NO:1 or its conserved alternative sequence; and / or the engineered immune cells are selected from T cells, NK cells, or immune cells derived from iPSC-induced differentiation.

3. The engineered immune cells according to claim 2, characterized in that, The chimeric antigen receptor comprises: an antigen-binding domain, a hinge region, a transmembrane domain, at least one co-stimulatory signaling domain, and a CD3ζ signaling domain; the co-stimulatory signaling domain is selected from CD28, 4-1BB, ICOS, OX40, CD27, or a combination thereof.

4. The engineered immune cells according to claim 3, characterized in that, The nucleotide sequence of the chimeric antigen receptor comprises the sequence shown in SEQ ID NO:2 or SEQ ID NO:5; or the nucleotide sequence of the exogenous T cell receptor comprises the sequence shown in SEQ ID NO:

4.

5. The engineered immune cells according to any one of claims 1-4, characterized in that, The engineered immune cells are selected from CAR-NK cells, iPSC-NK cells, iPSC-T cells, CAR-T cells, TCR-T cells, tumor-infiltrating lymphocytes (TILs), or γδ-T cells.

6. The method for constructing engineered immune cells according to any one of claims 1 to 5, characterized in that, include: The steps of introducing the LHX2 gene into immune cells in vitro or in vivo and overexpressing it.

7. The construction method according to claim 6, characterized in that, The LHX2 gene is introduced into immune cells via a viral vector or a non-viral vector; the viral vector is a lentiviral vector or a retroviral vector; the non-viral vector is a transposon system or mRNA.

8. A pharmaceutical composition, characterized in that, It comprises the engineered immune cells as described in any one of claims 1 to 5 and a pharmaceutically acceptable carrier or excipient.

9. The use of the engineered immune cells according to any one of claims 1 to 5 or the pharmaceutical composition according to claim 8 in the preparation of an immunotherapeutic drug.

10. The application according to claim 9, characterized in that, The diseases treated by the drug are selected from tumors, autoimmune diseases, or inflammatory diseases.